NCT00728390View on ClinicalTrials.gov

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 15, 2008

Primary Completion Date

August 9, 2011

Study Completion Date

January 29, 2013

Conditions
Carcinoma, Non-Small CellNeoplasm Metastasis
Interventions
DRUG

PF-00299804

CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.

Trial Locations (5)

14221

Pfizer Investigational Site, Amherst

14263

Pfizer Investigational Site, Buffalo

28050

Pfizer Investigational Site, Madrid

78229

Pfizer Investigational Site, San Antonio

94805

Pfizer Investigational Site, Villejuif

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00728390 - A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks | Biotech Hunter | Biotech Hunter